Allergy Therapeutics said its was trading in line with its expectations, with first-half revenues to rise 4.4% to £42.2m.
On constant currency terms, revenue would rise by 1.3%.
'The group has continued to grow in the past six months of 2017, notwithstanding an abnormally weak pollen season in Central Europe,' the company said.
At December 31, Allergy had cash of £25.8m, down from £27.8m a year earlier.
At 2:54pm: (LON:AGY) Allergy Therapeutics PLC share price was -0.25p at 29.75p